Présentation de l'entreprise
IM Cannabis Corp. operates within the Healthcare sector, specifically functioning in the industry of Drug Manufacturers - Specialty & Generic, where it focuses on the breeding, growing, and supply of medical cannabis products. The company serves medical patients in Israel and Germany by providing dried flowers and cannabis extracts distributed under the IMC, BLKMT, WAGNERS, and LOT420 brands. According to available financial data, the entity holds a market capitalization of $2.12 million and generated annual revenue of $54.73 million over the trailing twelve months. While the available facts do not specify an employee count, the organization's valuation indicates a small-cap status, suggesting it operates as a specialized player in a niche market rather than a large-scale commercial enterprise. This combination of a modest market cap and significant annual revenue relative to its size highlights a company that generates substantial top-line activity while maintaining a valuation profile typical of early-stage or specialized biotech firms that have yet to achieve profitability.
Santé financière
The company reported a revenue of $54.73 million for the trailing twelve months, yet it recorded a net income of -$11,319,000 and an EBITDA of -$4,559,000, revealing a cost structure where operating expenses significantly exceed gross profits. The gap between the $54.73 million in revenue and the substantial net loss indicates high overhead costs associated with manufacturing and distribution within the medical cannabis sector. Free cash flow stood at -$431,875, which implies that the company is currently burning cash and lacks the immediate liquidity to fund operations without external financing. In terms of profitability margins, the gross margin is 17.7%, while the operating margin is -31.4% and the profit margin is -20.7%, indicating that the company struggles to cover its operating expenses and deliver earnings to shareholders. The balance sheet shows a cash position of $2.73 million against a total debt load of $16.27 million, suggesting a leveraged position where liabilities exceed liquid assets. Although the debt-to-equity ratio is listed as N/A, the current ratio of 0.67 indicates that current liabilities exceed current assets, pointing to potential short-term liquidity challenges. Furthermore, Return on Equity is N/A due to the net loss position, while Return on Assets is -10.9%, which reveals that the company's assets are currently generating negative returns for its investors.
Évaluation de la valorisation
Valuation metrics for IM Cannabis Corp. present a mixed picture, with a P/E Ratio (TTM) of N/A and a Forward P/E of -0.26, the latter implying negative expected earnings in the near term. The Price to Book ratio is -0.75, which indicates that the market values the company at a negative multiple of its book value, reflecting the net loss position rather than a standard market premium. Alternative valuation measures include a Price to Sales ratio of 0.04 and an EV/EBITDA of -3.46, suggesting that the stock trades at a fraction of its sales revenue due to the lack of profitability. Price metrics show a 52-Week High of $7.12 and a 52-Week Low of $0.29, placing the current trading price significantly closer to the low end of the historical range given the negative forward multiples. The stock exhibits a Beta of 2.27, meaning its price volatility is more than twice that of the broader market, making it highly sensitive to market swings. These metrics collectively suggest a high-risk, high-volatility asset where traditional valuation multiples are distorted by the company's unprofitable operational status.
Growth & Income
IM Cannabis Corp. demonstrated a Revenue Growth (YoY) of 17.6%, while Earnings Growth (YoY) is N/A due to the company's net loss, implying that top-line expansion has not yet translated into bottom-line profitability. As a non-dividend payer, the company does not distribute a Dividend Yield or maintain a Payout Ratio of 0.0%, indicating that it retains all earnings—or in this case, absorbs losses—to fund operations and potentially invest in future growth initiatives. The overall growth and income profile is characterized by strong revenue expansion in the medical cannabis sector coupled with persistent operational losses and a lack of dividend income for shareholders. This profile is typical for specialty drug manufacturers in the early phases of market penetration where capital reinvestment is prioritized over shareholder returns.